Natera, Inc. (NTRA)
| Market Cap | 28.75B +30.8% |
| Revenue (ttm) | 2.50B +36.6% |
| Net Income | -226.32M |
| EPS | -1.64 |
| Shares Out | 143.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 723,529 |
| Open | 205.47 |
| Previous Close | 203.19 |
| Day's Range | 198.83 - 209.00 |
| 52-Week Range | 131.81 - 256.36 |
| Beta | 1.57 |
| Analysts | Strong Buy |
| Price Target | 260.89 (+29.97%) |
| Earnings Date | May 7, 2026 |
About NTRA
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizo... [Read more]
Financial Performance
In 2025, Natera's revenue was $2.31 billion, an increase of 35.90% compared to the previous year's $1.70 billion. Losses were -$208.16 million, 9.31% more than in 2024.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price target is $260.89, which is an increase of 29.97% from the latest price.
News
Natera to Launch Enhanced Panorama™ NIPT, Powered by Novel SNP-Informed Deep Sequencing Technology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive p...
Natera to Present 35 Studies at ASCO, Extending Clinical Data Leadership in Oncology
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a landmark oncology data program for the 2026 American Society of ...
Natera announces expansion into Austin, creating largest sequencing factory
Natera (NTRA) announced a significant expansion of its operations. At its North Austin headquarters campus, Natera will unveil two major expansion projects: a sequencing facility, significantly increa...
Natera Announces Expansion in Austin, Creating What Is Believed to Be the Largest Sequencing Facility in the World
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a significant expansion of its operations, marking a major milesto...
Natera announces Expand trial enrolled over 2,000 patients
Natera (NTRA) announced that the Expand clinical trial has enrolled over 2,000 patients, more than doubling enrollment in the last 12 months. Expand is a prospective, blinded, multi-site clinical tria...
EXPAND Trial of Natera's Fetal Focus™ Single-Gene NIPT Surpasses >2,000 Patients Enrolled
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced that the EXPAND clinical trial has enrolled over 2...
Signatera CDx approved by FDA as companion diagnostic in MIBC
Natera (NTRA) announced that the U.S. Food and Drug Administration has approved Signatera CDx as a companion diagnostic for use with adjuvant atezolizumab immunotherapy in MIBC. “This is the first…
Signatera™ CDx Approved by the FDA as a Companion Diagnostic in Muscle-Invasive Bladder Cancer (MIBC)
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has approved Sign...
The Cancer Test That Wall Street Is Betting On
One company has a big early lead in blood tests that detect cancer returning in survivors.
Cathie Wood’s ARK Investment buys 17.3K shares of Natera today
21:34 EDT Cathie Wood’s ARK Investment buys 17.3K shares of Natera (NTRA) today
Natera price target raised to $249 from $240 at Piper Sandler
Piper Sandler raised the firm’s price target on Natera (NTRA) to $249 from $240 and keeps an Overweight rating on the shares. The firm notes the company has $1B in…
AI, Obesity Drugs, and Diagnostics Fuel Healthcare Growth
Healthcare is regaining momentum as innovation—especially AI‑driven drug discovery—creates new growth opportunities, according to Shivani Vohra. She points to obesity treatments from Eli Lilly (LLY) a...
Natera Q1 Earnings Call Highlights
Natera NASDAQ: NTRA reported first-quarter 2026 revenue of $697 million, up 39% year over year, as the company delivered more than 1 million total units in a single quarter for the first time. Chief E...
Natera price target raised to $270 from $250 at Evercore ISI
Evercore ISI raised the firm’s price target on Natera (NTRA) to $270 from $250 and keeps an Outperform rating on the shares.
Natera price target raised to $265 from $257 at Baird
Baird raised the firm’s price target on Natera (NTRA) to $265 from $257 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results and…
Natera price target raised to $265 from $260 at JPMorgan
JPMorgan raised the firm’s price target on Natera (NTRA) to $265 from $260 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q1…
Natera price target raised to $265 from $260 at JPMorgan
JPMorgan raised the firm’s price target on Natera (NTRA) to $265 from $260 and keeps an Overweight rating on the shares.
Natera price target raised to $220 from $215 at Wells Fargo
Wells Fargo analyst Brandon Couillard raised the firm’s price target on Natera (NTRA) to $220 from $215 and keeps an Equal Weight rating on the shares. The firm notes Q1…
Natera reports Q1 EPS -60c, consensus -55c
Reports Q1 revenue $696.6M, consensus $617.07M. The company said, “We had an outstanding first quarter, reaching over one million units processed in a single quarter for the first time and…
Natera sees 2026 revenue $2.74B-$2.82B, consensus $2.67B
Sees 2026 gross margin to 64%-66%.
Natera Earnings Call Transcript: Q1 2026
Q1 2026 revenue grew 39% year-over-year to $697M, with record unit volumes and gross margins just under 65%. Oncology and women's health drove growth, ASPs rose, and guidance for revenue and margins was raised. Japan CRC launch and expanded MRD coverage present major future opportunities.
Natera Slides: Q1 2026
Natera has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Natera Earnings release: Q1 2026
Natera released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Natera Quarterly report: Q1 2026
Natera has published its Q1 2026 quarterly earnings report on May 7, 2026.
Natera Reports First Quarter 2026 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2026. Rece...